Clinical Trials Directory

Trials / Completed

CompletedNCT02870218

Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
150 (actual)
Sponsor
Rose Research Center, LLC · Industry
Sex
All
Age
21 Years – 65 Years
Healthy volunteers
Accepted

Summary

Three hundred-twenty (320) adult smokers of menthol or non-menthol combustible cigarettes will be recruited and randomly assigned to one of five groups (n=64/group), who will be asked to switch for 12 weeks to ad libitum use of combustible cigarettes (matched to subjects' menthol preference) containing either 0.4, 1.4, 2.5, 5.6 or 16.9 mg nicotine (standardized nicotine yields ranging from 0.02-0.80 mg/cigarette), respectively. Each group will include 32 heavy (≥ 20 cigarettes/day), and 32 light smokers (≤10 cigarettes/day), who are hypothesized to be more sensitive to nicotine's reinforcing effects. Participants will also have free access to nicotine-containing e-cigarettes (JUUL) throughout the 12-week period. Abuse liability of combustible cigarettes will be assessed by behavioral (cigarettes/day, time to first cigarettes), self-report (rewarding effects, withdrawal symptoms) and biochemical indices (expired air carbon monoxide, cotinine blood sampling). In laboratory sessions, we will measure nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking. This study is designed to help the FDA identify a target nicotine threshold that will not attract young people to smoking or induce relapse in former smokers. Additionally, we will determine the level of cigarette nicotine reduction that will be tolerated without inducing dissatisfaction in smokers, information that is relevant to the FDA for designing a stepwise nicotine reduction policy that can be implemented without widespread objections. The knowledge gained from this project will greatly increase our knowledge of nicotine addiction and will help frame an FDA policy relating to the regulation of the nicotine content of tobacco. Ultimately, a well-designed nicotine reduction policy has the potential to greatly reduce the enormous toll of death and disease caused by cigarette smoking.

Conditions

Interventions

TypeNameDescription
DRUGSmoking research cigarettes with e-cigaretteSmoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
DRUGNicotine discrimination thresholdsMeasure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.

Timeline

Start date
2019-05-01
Primary completion
2021-07-28
Completion
2021-07-28
First posted
2016-08-17
Last updated
2022-01-14

Locations

2 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT02870218. Inclusion in this directory is not an endorsement.